Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Soonchunhyang University Hospital |
---|---|
Information provided by: | Soonchunhyang University Hospital |
ClinicalTrials.gov Identifier: | NCT00903357 |
The purpose of this study is to assess the clinical effectiveness of Montelukast in children (2~6 years old) with atopic dermatitis and identify the pathophysiologic background of Montelukast on the role of modulating the atopic dermatitis measured by urinary Leukotriene 4 (LTE4) and Eosinophil protein X.
Condition | Intervention |
---|---|
Atopic Dermatitis |
Drug: Placebo (ascorbic acid), following montelukast sodium Drug: Montelukast sodium, following placebo (ascorbic acid) |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Crossover Assignment, Efficacy Study |
Official Title: | A Double Blind, Randomized, Crossover Study to Compare the Effectiveness of Montelukast on Atopic Dermatitis in Koreans |
Estimated Enrollment: | 54 |
Study Start Date: | June 2009 |
Estimated Study Completion Date: | May 2010 |
Estimated Primary Completion Date: | February 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Group A: Experimental
Group A received active medication (montelukast 4 mg each day) for 8 weeks followed by a crossover to 8 weeks of placebo after 2-weeks washout period.
|
Drug: Montelukast sodium, following placebo (ascorbic acid)
Patients in Group A will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks.
|
Group B: Experimental
Group B received placebo medication (ascorbic acid) for 8 weeks followed by a crossover to 8 weeks of active medication (montelukast 4 mg each day) after 2-weeks washout period.
|
Drug: Placebo (ascorbic acid), following montelukast sodium
Patients in Group B will receive chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks.
|
Leukotriene B4 (LTB4) and the cysteinyl-leukotrienes LTC4, LTD4 and LTE4 are potent proinflammatory mediators derived from arachidonic acid through the 5- lipoxygenase pathway. They are secreted from eosinophils and other inflammatory cells such as mast cells and macrophages. The primary action of leukotrienes includes contraction of human airway muscle, chemotaxis, and increased vascular permeability, with secondary effects of inhibiting allergen-induced early and late responses. Several in vivo and in vitro studies suggest a role for cysteinyl leukotrienes in the pathogenesis of atopic dermatitis and there is a rationale for the use of pharmacological agents to antagonize their effects in the treatment of atopic dermatitis. Levels of LTE4 measured in urine (Urinary-LTE4) may be a useful measure of whole-body cysteinyl-leukotriene production in vivo, because that LTE4 is a stable urinary metabolite of LTC4 and LTD4. Urinary-LTE4 has been measured in individuals with atopic dermatitis, but in small-scale studies, and the results are conflicting.
Ages Eligible for Study: | 2 Years to 6 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Bok Yang Pyun, M.D., PhD | +82-2-709-9340 | bypyun@hosp.sch.ac.kr |
Contact: Hyeon Jong Yang, M.D. | +82-2-709-9339 | ilove902@hanmail.net |
Korea, Republic of | |
Pediatric Allergy & Respiratory Center, Department of Pediatrics, Soonchunhyang University Hospital | |
Seoul, Korea, Republic of, 140-743 |
Study Chair: | Bok Yang Pyun, M.D., PhD. | Pediatric Allergy & Respiratory Center, Department of Pediatrics, Soonchunhyang University Hospital |
Responsible Party: | Pediatric Allergy & Respiratory Center, Soonchunhyang University Hospital ( Pediatric Allergy & Respiratory Center, Department of Pediatrics, Soonchunhyang University Hospital ) |
Study ID Numbers: | schallergy |
Study First Received: | May 14, 2009 |
Last Updated: | May 14, 2009 |
ClinicalTrials.gov Identifier: | NCT00903357 History of Changes |
Health Authority: | Korea: Food and Drug Administration |
Atopic dermatitis Montelukast |
Dermatitis, Atopic Antioxidants Skin Diseases Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Anti-Asthmatic Agents Trace Elements Hormones Leukotriene Antagonists Vitamin C |
Montelukast Hypersensitivity Genetic Diseases, Inborn Vitamins Hypersensitivity, Immediate Skin Diseases, Eczematous Micronutrients Skin Diseases, Genetic Ascorbic Acid Dermatitis |
Respiratory System Agents Antioxidants Dermatitis, Atopic Molecular Mechanisms of Pharmacological Action Hormone Antagonists Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Leukotriene Antagonists Hypersensitivity Vitamins Therapeutic Uses Skin Diseases, Eczematous Micronutrients |
Skin Diseases, Genetic Dermatitis Immune System Diseases Skin Diseases Growth Substances Anti-Asthmatic Agents Protective Agents Pharmacologic Actions Montelukast Genetic Diseases, Inborn Hypersensitivity, Immediate Ascorbic Acid |